Novo Nordisk’s once-a-day sickle cell disease drug etavopivat cut the rate of pain crises in a yearlong mid-stage study. The ...

Catal­ent re­port­ed a slight rev­enue up­swing dur­ing its lat­est quar­ter­ly re­sults, which CEO Alessan­dro Masel­li ...